BACKGROUND: Some have recommended against routine screening for colorectal cancer (CRC) among patients ≥75 years of age, while others have suggested that screening colonoscopy (SC) is less beneficial for women than men. We estimated the expected benefits (decreased mortality from CRC) and harms (SC-related mortality) of SC based on sex, age, and comorbidity. OBJECTIVE: To stratify older patients according to expected benefits and harms of SC based on sex, age, and comorbidity. DESIGN: Retrospective study using Medicare claims data. PARTICIPANTS: Medicare beneficiaries 67-94 years old with and without CRC. MAIN MEASURES: Life expectancy, CRC- and colonoscopy-attributable mortality rates across strata of sex, age, and comorbidity, pay-off time (i.e. the minimum time until benefits from SC exceeded harms), and life-years saved for every 100,000 SC. KEY RESULTS: Increasing age and comorbidity were associated with lower CRC-attributable mortality. Due to shorter life expectancy and CRC-attributable mortality, the benefits associated with SC were substantially lower among patients with greater comorbidity. Among men aged 75-79 years with no comorbidity, the number of life-years saved was 459 per 100,000 SC, while men aged 67-69 with ≥3 comorbidities had 81 life-years saved per 100,000 SC. There was no evidence that SC was less effective in women. Among men and women 75-79 with no comorbidity, number of life-years saved was 459 and 509 per 100,000 SC, respectively; among patients with ≥3 comorbidities, there was no benefit for either men or women. CONCLUSIONS: Although the effectiveness of SC was equivalent for men and women, there was substantial variation in SC effectiveness within age groups, arguing against screening recommendations based solely on age.
BACKGROUND: Some have recommended against routine screening for colorectal cancer (CRC) among patients ≥75 years of age, while others have suggested that screening colonoscopy (SC) is less beneficial for women than men. We estimated the expected benefits (decreased mortality from CRC) and harms (SC-related mortality) of SC based on sex, age, and comorbidity. OBJECTIVE: To stratify older patients according to expected benefits and harms of SC based on sex, age, and comorbidity. DESIGN: Retrospective study using Medicare claims data. PARTICIPANTS: Medicare beneficiaries 67-94 years old with and without CRC. MAIN MEASURES: Life expectancy, CRC- and colonoscopy-attributable mortality rates across strata of sex, age, and comorbidity, pay-off time (i.e. the minimum time until benefits from SC exceeded harms), and life-years saved for every 100,000 SC. KEY RESULTS: Increasing age and comorbidity were associated with lower CRC-attributable mortality. Due to shorter life expectancy and CRC-attributable mortality, the benefits associated with SC were substantially lower among patients with greater comorbidity. Among men aged 75-79 years with no comorbidity, the number of life-years saved was 459 per 100,000 SC, while men aged 67-69 with ≥3 comorbidities had 81 life-years saved per 100,000 SC. There was no evidence that SC was less effective in women. Among men and women 75-79 with no comorbidity, number of life-years saved was 459 and 509 per 100,000 SC, respectively; among patients with ≥3 comorbidities, there was no benefit for either men or women. CONCLUSIONS: Although the effectiveness of SC was equivalent for men and women, there was substantial variation in SC effectiveness within age groups, arguing against screening recommendations based solely on age.
Authors: Harminder Singh; Zoann Nugent; Alain A Demers; Erich V Kliewer; Salaheddin M Mahmud; Charles N Bernstein Journal: Gastroenterology Date: 2010-06-20 Impact factor: 22.682
Authors: Michael Pignone; Melissa Rich; Steven M Teutsch; Alfred O Berg; Kathleen N Lohr Journal: Ann Intern Med Date: 2002-07-16 Impact factor: 25.391
Authors: Sameer D Saini; Adam A Powell; Jason A Dominitz; Deborah A Fisher; Joseph Francis; Linda Kinsinger; Kathleen S Pittman; Philip Schoenfeld; Stephanie E Moser; Sandeep Vijan; Eve A Kerr Journal: J Gen Intern Med Date: 2016-04 Impact factor: 5.128
Authors: Kathryn A Martinez; Craig E Pollack; Darcy F Phelan; Diane Markakis; Lee Bone; Gary Shapiro; Jennifer Wenzel; Mollie Howerton; Lawrence Johnson; Mary A Garza; Jean G Ford Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-04-29 Impact factor: 4.254
Authors: Carolyn J Presley; Pamela R Soulos; Mary Tinetti; Victor M Montori; James B Yu; Cary P Gross Journal: J Oncol Pract Date: 2016-12-20 Impact factor: 3.840
Authors: Carmen L Lewis; Denise Esserman; Christopher DeLeon; Michael P Pignone; Donald E Pathman; Carol Golin Journal: J Gen Intern Med Date: 2013-03-29 Impact factor: 5.128
Authors: Erica S Breslau; Sherri Sheinfeld Gorin; Heather M Edwards; Mara A Schonberg; Nicole Saiontz; Louise C Walter Journal: J Gen Intern Med Date: 2016-03-03 Impact factor: 5.128